Page 140 - Read Online

Tsutsui et al. Hepatoma Research 2018;4:13 Hepatoma Research
DOI: 10.20517/2394-5079.2018.20

Original Article Open Access

Neoadjuvant hepatic arterial infusion chemotherapy
for resectable hepatocellular carcinomas

1
6
5
4
Rina Tsutsui , Hiroaki Nagamatsu , Osamu Itano , Akihiro Deguchi , Tsubasa Tsutsumi , Mamoru Hiraki ,
3
2
Naohisa Mizukami , Jun Akiba 8
7
1 Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo 193-0998, Japan.
2 Department of Gastroenterology, Juntendo University Hospital, Tokyo 113-8431, Japan.
3 Department of Hepato-Biliary-Pancreatic and Gastroenterological Surgery, International University of Health and Welfare School of
Medicine, Chiba 286-8686, Japan.
4 Department of Medicine, Kagawa Rosai Hospital, Kagawa 763-0013, Japan.
5 Department of Medicine, Kurume University School of Medicine, Fukuoka 830-0011, Japan.
6 Department of Surgery, Yame General Hospital, Fukuoka 834-0034, Japan
7 Department of Radiology, Yame General Hospital, Fukuoka 834-0034, Japan
8 Department of Pathology, Kurume University School of Medicine, Fukuoka 830-0011, Japan.
Correspondence to: Dr. Hiroaki Nagamatsu, Department of Gastroenterology, Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku,
Tokyo 113-8431, Japan. E-mail: h-nagamatsu@juntendo.ac.jp
How to cite this article: Tsutsui R, Nagamatsu H, Itano O, Deguchi A, Tsutsumi T, Hiraki M, Mizukami N, Akiban J. Neoadjuvant hepatic
arterial infusion chemotherapy for resectable hepatocellular carcinomas. Hepatoma Res 2018;4:13.
http://dx.doi.org/10.20517/2394-5079.2018.20

Received: 15 Mar 2018 First Decision: 10 Apr 2018 Revised: 3 May 2018 Accepted: 7 May 2018 Published: 11 May 2018
Science Editor: Guang-Wen Cao Copy Editor: Guang-Zhe Zhu Production Editor: Huan-Liang Wu

Abstract
Aim: To evaluate the effect of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) on the survival of
patients with resectable hepatocellular carcinoma (HCC).

Methods: Between January 2003 and January 2014, 80 patients underwent hepatic resection for HCC. Of these
patients, we evaluated 49 patients who met the following inclusion criteria: (1) preserved liver function (Child-
Pugh A); (2) resectable HCC (≤ 3 nodules, regardless of the size); and (3) HCC with high-grade malignant
potential. Among them, 13 patients underwent neoadjuvant HAIC and curative hepatectomy (treatment group).
The remaining 36 patients underwent curative hepatic resection without neoadjuvant therapy (control group).
Survival after hepatic resection was compared retrospectively between the groups.

Results: During follow-up, 2 (15.4%) patients in the treatment group and 25 (69.4%) patients in the control group
developed recurrence. The 1-, 3-, and 5-year disease-free rates (100%, 78.6%, and 78.6%, respectively vs. 65.8%,
33.7%, and 26.6%, respectively; P = 0.003) and overall survival rates (100%, 100%, and 100%, respectively vs.
91.7%, 77.8%, and 55.3%, respectively; P = 0.037) were significantly better in the treatment group than in the
control group.

© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.hrjournal.net